nach oben

Erschienen in:

2021 | Antidepressiva | OriginalPaper | Buchkapitel

1. Antidepressiva

verfasst von : Dr. med. Francesca Regen, Otto Benkert

Erschienen in: Kompendium der Psychiatrischen Pharmakotherapie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden einmal im allgemeinen Teil und dann für jedes Antidepressivum spezifisch im Präparateteil beschrieben. Jedes Präparat wird bewertet. In einem eigenen Abschnitt werden die Unterschiede der Antidepressiva in Bezug auf Wirksamkeit und Nebenwirkungen analysiert. Alle Indikationen für Antidepressiva, von den depressiven Störungen über die Angst- und Zwangsstörungen bis zu den Trauma- und belastungsbezogenen Störungen, werden abgehandelt. Der Schwerpunkt liegt auch in dieser Auflage im praktischen Umgang mit Antidepressiva.

Andrews G, Basu A, Cuijpers P et al (2018) Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: an updated meta-analysis. J Anxiety Disord 55: 70–78PubMedCrossRef

Bandelow B, Sagebiel A, Belz M et al (2018) Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. Br J Psychiatry 212(6):333–338PubMedCrossRef

Bartels C, Wagner M, Wolfsgruber S et al; Alzheimer’s Disease Neuroimaging Initiative (2018) Impact of SSRI therapy on risk of conversion from mild cognitive impairment to Alzheimer’s dementia in individuals with previous depression. Am J Psychiatry 175(3):232–241CrossRef

Batelaan NM, Bosman RC, Muntingh A et al (2017) Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ 358:j3927PubMedPubMedCentralCrossRef

Bockting CLH, Klein NS, Elgersma HJ et al (2018) Effectiveness of preventive cognitive therapy while tapering antidepressants versus maintenance antidepressant treatment versus their combination in prevention of depressive relapse or recurrence (DRD study): a three-group, multicentre, randomised controlled trial. Lancet Psychiatry 5(5):401–410PubMedCrossRef

Boland EM, Rao H, Dinges DF et al (2017) Meta-analysis of the antidepressant effects of acute sleep deprivation. J Clin Psychiatry 78(8):e1020–e1034PubMedCrossRef

Brännström J, Lövheim H, Gustafson Y et al (2019) Association between antidepressant drug use and hip fracture in older people before and after treatment initiation. JAMA Psychiatry 76(2):172–179PubMedPubMedCentralCrossRef

Brouwer A, Nguyen HT, Snoek FJ et al (2017) Light therapy: is it safe for the eyes? Acta Psychiatr Scand 136(6):534–548PubMedCrossRef

Brunet A, Saumier D, Liu A et al (2018) Reduction of PTSD symptoms with pre-reactivation propranolol therapy: a randomized controlled trial. Am J Psychiatry 175(5):427–433PubMedCrossRef

Bykov K, Schneeweiss S, Donneyong MM et al (2017) Impact of an interaction between clopidogrel and selective serotonin reuptake inhibitors. Am J Cardiol 119(4):651–657PubMedCrossRef

Cipriani A, Furukawa TA, Salanti G et al (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391(10128):1357–1366PubMedPubMedCentralCrossRef

Dakwar E, Nunes EV, Hart CL et al (2019) A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial. Am J Psychiatry 176(11):923–930PubMedCrossRef

Dakwar E, Levin F, Hart CL et al (2020) A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. Am J Psychiatry 177(2):125–133PubMedCrossRef

DeRubeis RJ, Zajecka J, Shelton RC et al (2019) Depressive episode with antidepressant medication alone or in combination with cognitive behavioral therapy: a phase 2 randomized clinical trial. Jama Psychiatry 77(3):237–245CrossRefPubMedCentral

DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW, Leitliniengruppe Unipolare Depression (2015) S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression – Langfassung, 2. Aufl. Version 5. https://www.leitlinien.de/nvl/depression. Zugegriffen: 11. März 2018

Douros A, Dell’Aniello S, Dehghan G et al (2019) Degree of serotonin reuptake inhibition of antidepressants and ischemic risk: a cohort study. Neurology 93(10):e1010–e1020PubMedPubMedCentralCrossRef

Dragioti E, Solmi M, Favaro A et al (2019) Association of antidepressant use with adverse health outcomes: a systematic umbrella review. JAMA Psychiatry 76(12):1241–1255PubMedPubMedCentralCrossRef

Dudas R, Malouf R, McCleery J, Dening T (2018) Antidepressants for treating depression in dementia. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003944.pub2CrossRefPubMedPubMedCentral

Dunlop BW, LoParo D, Kinkead B et al (2019) Benefits of sequentially adding cognitive-behavioral therapy or antidepressant medication for adults with nonremitting depression. Am J Psychiatry 176(4):275–286PubMedPubMedCentralCrossRef

Fava GA, Cosci F (2019) Understanding and managing withdrawal syndromes after discontinuation of antidepressant drugs. J Clin Psychiatry 80(6):19com12794PubMed

Fava M, Freeman MP, Flynn M et al (2018) Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry 25(7):1592–1603PubMedPubMedCentralCrossRef

Fernandes N, Prada L, Rosa MM et al (2020) The impact of SSRIs on mortality and cardiovascular events in patients with coronary artery disease and depression: systematic review and meta-analysis. Clin Res Cardiol. Online ahead of print

Firth J, Teasdale SB, Allott K et al (2019) The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry 18(3):308–324PubMedPubMedCentralCrossRef

FOCUS Trial Collaboration (2019) Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet 393(10168):265–274CrossRef

Fu Y, Dai Q, Zhu L, Wu S (2018) Antidepressants use and risk of cataract development: a systematic review and meta-analysis. BMC Ophthalmol 18(1):31PubMedPubMedCentralCrossRef

Furukawa TA, Cipriani A, Cowen PJ et al (2019) Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry 6(7):601–609PubMedPubMedCentralCrossRef

Gunduz-Bruce H, Silber C, Kaul I et al (2019) Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med 81(10):903–911CrossRef

Henssler J, Heinz A, Brandt L, Bschor T (2019) Antidepressant withdrawal and rebound phenomena. Dtsch Arztebl Int 116(20):355–361PubMedPubMedCentral

Hiemke C, Bergemann N, Clement HW et al (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51(1-02):9–62PubMed

Hieronymus F, Lisinski A, Nilsson S et al (2019) Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis. Lancet Psychiatry 6(9):745–752PubMedCrossRef

Horowitz MA, Taylor D (2019) Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 6(6):538–546PubMedCrossRef

Jakubovski E, Varigonda AL, Freemantle N et al (2016) Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. Am J Psychiatry 173(2):174–183PubMedCrossRef

Kessler DS, MacNeill SJ, Tallon D (2018) Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). BMJ 363: k4218PubMedPubMedCentralCrossRef

Karyotaki E, Riper H, Twisk J et al (2017) Efficacy of self-guided internet-based cognitive behavioral therapy in the treatment of depressive symptoms: a meta-analysis of individual participant data. JAMA Psychiatry 74(4):351–359PubMedCrossRef

Khan A, Fahl Mar K, Faucett J et al (2017) Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987–2013. World Psychiatry 16(2):181–192PubMedPubMedCentralCrossRef

Köhler-Forsberg O, Lydholm NC, Hjorthøj C et al (2019a) Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatr Scand 139(5):404–419PubMedCrossRef

Köhler-Forsberg O, Gasse C, Petersen L et al (2019b) Statin treatment and the risk of depression. J Affect Disord 246:706–715PubMedCrossRef

Kraglund KL, Mortensen JK, Damsbo AG et al (2018) Neuroregeneration and vascular protection by citalopram in acute ischemic stroke (TALOS). Stroke 49(11):2568–2576PubMedCrossRef

Kupfer DJ (1991) Long-term treatment of depression. J Clin Psychiatry 52(Suppl 5):28–34PubMed

Lazarov A, Pine DS, Bar-Haim Y (2017) Gaze-contingent music reward therapy for social anxiety disorder: a randomized controlled trial. Am J Psychiatry 174(7):649–656PubMedCrossRef

Lejoyeux M, Matharan S, de Bodinat C (2015) How to switch to agomelatine after an unsuccessful try with paroxetine or venlafaxine. CNS Spectr 20(1):29–38PubMedCrossRef

Mataix-Cols D, Fernández de la Cruz L, Monzani B, DCS Anxiety Consortium, Altemus M, Anderson P, Cukor J et al (2017) D-Cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data. Jama Psychiatry 74(5):501–510PubMedCrossRef

McClintock SM, Reti IM, Carpenter LL et al; National Network of Depression Centers rTMS Task Group; American Psychiatric Association Council on Research Task Force on Novel Biomarkers and Treatments (2018) Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. J Clin Psychiatry 79(1):16cs10905

Meister R, Jansen A, Berger M et al (2018) Psychotherapie depressiver Störungen. Verfahren, Evidenz und Perspektiven. Nervenarzt 89(3):241–251PubMedCrossRef

Merz J, Schwarzer G, Gerger H (2019) Comparative efficacy and acceptability of pharmacological, psychotherapeutic, and combination treatments in adults with posttraumatic stress disorder: a network meta-analysis. JAMA Psychiatry 76(9):904–913PubMedPubMedCentralCrossRef

Orlova Y, Rizzoli P, Loder E (2018) Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurol 75(5):566–572PubMedPubMedCentralCrossRef

Paulzen M, Haen E, Hiemke C et al (2018) Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism. J Affect Disord 227:506–511PubMedCrossRef

Phillips JL, Norris S, Talbot J et al (2019) Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am J Psychiatry 176(5):401–409PubMedCrossRef

Phillips JL, Norris S, Talbot J et al (2020) Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology 45(4):606–612PubMedCrossRef

Rauch SAM, Kim HM, Powell C et al (2019) Efficacy of prolonged exposure therapy, sertraline hydrochloride, and their combination among combat veterans with posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 76(2):117–126PubMedCrossRef

Reiff CM, Richman EE, Nemeroff CB et al; and the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research (2020) Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry 177(5):391–410CrossRef

Renoux C, Vahey S, Dell’Aniello S, Boivin JF (2017) Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol 74(2):173–180PubMedCrossRef

Rosenblat JD, Carvalho AF, Li M et al (2019) Oral ketamine for depression: a systematic review. J Clin Psychiatry 80(3):18r12475PubMedCrossRef

Rutten S, Vriend C, Smit JH et al (2019) Bright light therapy for depression in Parkinson disease: a randomized controlled trial. Neurology 92(11):e1145–e1156PubMed

Schäfer I, Gast U, Hofmann A et al (2019) S3-Leitlinie Postraumatische Belastungsstörung. Springer, Berlin Heidelberg New YorkCrossRef

Schlereth T et al (2019) Diagnose und nicht interventionelle Therapie neuropathischer Schmerzen, S2k-Leitlinie, 2019. In: Deutsche Gesellschaft für Neurologie (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie (Online: www.dgn.org/leitlinien (abgerufen am 09.03.2020))

Sharma T, Guski LS, Freund N, Gøtzsche PC (2016) Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ 352:i65PubMedPubMedCentralCrossRef

Slee A, Nazareth I, Bondaronek P et al (2019) Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet 393(10173):768–777PubMedCrossRef

Stingl JC, Brockmöller J (2013) Personalisierte Pharmakotherapie. Evidenzbasierte Leitlinien und klinische Anwendung pharmakogenetischer Diagnostik. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56(11):1509–1521PubMedCrossRef

Taylor JH, Landeros-Weisenberger A et al (2018) Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial. Neuropsychopharmacology 43(2):325–333PubMedCrossRef

Undurraga J, Baldessarini RJ (2017) Direct comparison of tricyclic and serotonin-reuptake inhibitor antidepressants in randomized head-to-head trials in acute major depression: Systematic review and meta-analysis. J Psychopharmacol 31(9):1184–1189PubMedCrossRef

Voican CS, Corruble E, Naveau S, Perlemuter G (2014) Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry 171(4):404–415PubMedCrossRef

Walther A, Breidenstein J, Miller R (2019) Association of testosterone treatment with alleviation of depressive symptoms in men: a systematic review and meta-analysis. JAMA Psychiatry 76(1):31–40PubMedCrossRef

Wenzel-Seifert K, Wittmann M, Haen E (2011) QTc prolongation by psychotropic drugs and the risk of Torsades de Pointes. Dtsch Arztebl Int 108(41):687–693PubMedPubMedCentral

Williams NR, Heifets BD, Blasey C et al (2018) Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry 175(12):1205–1215PubMedPubMedCentralCrossRef

Williams NR, Heifets BD, Bentzley BS et al (2019) Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Mol Psychiatry 24(12):1779–1786PubMedCrossRef

Wright JH, Owen JJ, Richards D et al (2019) Computer-assisted cognitive-behavior therapy for depression: a systematic review and meta-analysis. J Clin Psychiatry 80(2):18–r12188CrossRef

Yatham MS, Yatham KS, Ravindran AV et al (2019) Do statins have an effect on depressive symptoms? A systematic review and meta-analysis. J Affect Disord 257:55–63PubMedCrossRef

Zhou X, Ravindran AV, Qin B et al (2015) Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 76(4):e487–e498PubMedCrossRef

Zisook S, Johnson GR, Tal I et al (2019) General predictors and moderators of depression remission: a VAST-D Report. Am J Psychiatry 176(5):348–357PubMedCrossRef

Zoellner LA, Roy-Byrne PP, Mavissakalian M et al (2019) Doubly randomized preference trial of prolonged exposure versus sertraline for treatment of PTSD. Am J Psychiatry 176(4):287–296PubMedCrossRef

Titel: Antidepressiva
verfasst von: Dr. med. Francesca Regen
Otto Benkert
Verlag: Springer Berlin Heidelberg
Buch: Kompendium der Psychiatrischen Pharmakotherapie
Print ISBN: 978-3-662-61752-6

Electronic ISBN: 978-3-662-61753-3

Copyright-Jahr: 2021
DOI: https://doi.org/10.1007/978-3-662-61753-3_1

Passend zum Thema

Mittelgradige Depressionen & Johanniskraut: Das hat sich geändert

Affektive Störungen

Die Behandlungsempfehlungen bei mittelgradiger Depression wurden erneuert und der Einsatz von Johanniskraut entscheidend präzisiert – welche zwei Empfehlungen Sie aus der aktualisierten Depressions-Leitlinie jetzt kennen sollten.

3 Kernaussagen: Cochrane-Analyse untersucht Johanniskrautextrakte

Affektive Störungen

Johanniskraut gehört zu den am besten untersuchten pflanzlichen Arzneimitteln. Die Ergebnisse zur Wirksamkeit bei Depressionen wurden u. a. in einem Cochrane-Review analysiert [1]. Wie das pflanzliche Antidepressivum dabei abschnitt und welche drei Kernaussagen Sie für die Praxis kennen sollten, lesen Sie hier.

Depression behandeln. Natürlich.

Content Hub

Aktuelle Ergebnisse aus in-vitro- und in-vivo-Untersuchungen liefern detaillierte Erklärungen zum Wirkmechanismus von hochdosiertem Johanniskraut-Extrakt: Neu ist die Erkenntnis, dass der Johanniskraut-Extrakt bei chronischem Stress die deregulierte Stressantwort der überaktiven HPA-Achse sowie die Expression des Stressgens FKBP5 normalisieren kann. Mehr zum aktuellen Stand der Wissenschaft bei der Therapie von Depressionen erfahren Sie hier.